Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,919 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06990178Enrolling by invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
This trial is testing a new treatment approach for esophageal cancer that includes chemotherapy and immunotherapy before surgery. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Shenzhen, GuangdongAges 18–75 - NCT06901622Enrolling by invitationPhase 2
Testing a combination of drugs for advanced gallbladder and bile duct cancer
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
ZhengzhouAges 18–75 - NCT06848738Enrolling by invitation
Faster biopsy for lung cancer or lymphoma near the esophagus
This trial tests a faster way to get a tissue sample from lung cancer or lymphoma tumors that are near the esophagus or stomach. The goal is to start your treatment sooner by using a special ultrasound scope to do a biopsy right away.
NæstvedAges 18 years+ - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06447532Enrolling by invitation
Machine learning to track inflammation in breast cancer
This study uses a computer program to look at blood test results from women treated for breast cancer. The goal is to see if patterns in inflammation markers can help predict outcomes.
Buenos Aires, Buenos AiresAges 18–75 - NCT06437288Enrolling by invitationPhase 4
Light-activated drug therapy for returning esophageal cancer
This trial tests a treatment called hematoporphyrin photodynamic therapy (a light-activated drug) for people with esophageal cancer that has come back or not fully gone away after prior treatment. It aims to see if this therapy can safely destroy remaining cancer cells in the inner layers of the esophagus.
Guangzhou, GuangdongAges 18–80 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT06250777Enrolling by invitationPhase 2
T-DXd for HER2-mutant lung cancer with brain metastases
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
SeoulAges 20 years+ - NCT03459820Enrolling by invitationPhase 2/Phase 3
PET/CT scan study for high-risk or returning prostate cancer
This trial studies how a special PET/CT scan (using 18F-DCFPyL) helps evaluate prostate cancer that is either high-risk at diagnosis or has come back based on PSA blood tests. It may help your care team better stage (map) the cancer and guide next steps.
Montreal, QuebecAges 18 years+ - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Fayetteville, ArkansasAges 18–100 - NCT07049926RecruitingPhase 1/Phase 2
Combination therapy study for advanced kidney cancer
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
San Francisco, CaliforniaAges 18–120 - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Phoenix, ArizonaAges 18 years+ - NCT02582697RecruitingPhase 3
Faster vs standard chemotherapy for spreading germ cell tumors
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
Downey, CaliforniaAges 11–50 - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Bloomington, IllinoisAges 60 years+ - NCT07460986RecruitingPhase 1/Phase 2
Bexmarilimab plus doxorubicin for advanced soft-tissue sarcoma
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
BadalonaAges 18 years+ - NCT06108232RecruitingPhase 2
Study of two drugs for untreated follicular lymphoma
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Houston, TexasAges 18 years+ - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT04609046RecruitingPhase 1
Lenalidomide and nivolumab added to standard treatment for brain lymphoma
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
Los Angeles, CaliforniaAges 18 years+ - NCT05454618Recruiting
Deciding to join a pediatric cancer treatment trial
This study looks at the decision-making process for parents (or legal guardians) when their child is newly diagnosed with cancer and might consider enrolling in a treatment trial. It may help improve how families are informed and supported when making these choices.
Memphis, TennesseeAges Any age - NCT07793214Recruiting
Whole-body infrared hyperthermia for advanced solid tumors
This study looks at how well a treatment called whole-body infrared hyperthermia works for people with advanced solid tumors. The treatment uses heat to warm the whole body and may help fight cancer. The study will review medical records of people who already had this treatment at Zhejiang Hospital, and some people may join going forward.
Hangzhou, ZhejiangAges Any age - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Chandler, ArizonaAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,919 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.